Pomalidomide is an immunomodulatory drug for treatment of relapsed or refractory multiple myeloma (rrMM) in patients who often have comorbid renal conditions. To assess the impact of renal impairment on pomalidomide exposure, a population pharmacokinetics (PPK) model of pomalidomide in rrMM patients with various degrees of impaired renal function was developed. Intensive and sparse pomalidomide concentration data collected from two clinical studies in rrMM patients with normal renal function, moderately impaired renal function, severely impaired renal function not requiring dialysis, and with severely impaired renal function requiring dialysis were pooled over the dose range of 2 to 4 mg, to assess specifically the influence of the impaired renal function as a categorical variable and a continuous variable on pomalidomide clearance and plasma exposure. In addition, pomalidomide concentration data collected on dialysis days from both the withdrawal (arterial) side and from the returning (venous) side of the dialyzer, from rrMM patients with severely impaired renal function requiring dialysis, were used to assess the extent to which dialysis contributes to the removal of pomalidomide from blood circulation. PPK analyses demonstrated that moderate to severe renal impairment not requiring dialysis has no influence on pomalidomide clearance or plasma exposure, as compared to those patients with normal renal function, while pomalidomide exposure increased approximately 35% in patients with severe renal impairment requiring dialysis on nondialysis days. In addition, dialysis increased total body pomalidomide clearance from 5 L/h to 12 L/h, indicating that dialysis will significantly remove pomalidomide from the blood circulation. Thus, pomalidomide should be administered post-dialysis on the days of dialysis.
Introduction
The IMiD ® agent pomalidomide (Celgene Corporation, Summit, NJ, USA) has pleiotropic cytotoxic effects against multiple myeloma (MM) cells 1, 2 in addition to antiproliferative, 3, 4 antiangiogenic, [5] [6] [7] and immunomodulatory activity. 8, 9 Furthermore, pomalidomide has potent effects on key cytokines, including IL-10, IFNγ, and TNFα. 10 Pomalidomide has been studied for treatment of various hematologic and non-neoplastic hematologic disorders [11] [12] [13] and is approved (in combination with dexamethasone) in the European Union and United States for the treatment of patients with MM who have received ≥2 prior therapies, including lenalidomide and bortezomib (in the European Union; a proteasome inhibitor in the United States), and who have progressed on or within 60 days of completion of the last therapy or have disease progression on the submit your manuscript | www.dovepress.com
Dovepress

134
Li et al last therapy. 14, 15 This combination (pomalidomide plus lowdose dexamethasone) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone. 13 Thrombocytopenia, neutropenia, and anemia were the most common grade 3/4 adverse events.
Lenalidomide, pomalidomide's IMiD analog, is metabolized minimally and eliminated predominantly via urinary excretion in the unchanged form in humans, 16 resulting in dosage adjustments for patients with creatinine clearance (CrCl) <50 mL/min. 17, 18 Pomalidomide is eliminated predominantly through renal excretion (~73% of the administered dose), with <3% of the administered dose excreted in urine as unchanged pomalidomide across all dose levels. 19 Thus, it is relevant to assess the influence of renal impairment on pomalidomide clearance and plasma exposure.
Pomalidomide population pharmacokinetics (PPK) was previously assessed in both healthy individuals and patients with relapsed or refractory MM (rrMM). 20 Those analyses suggested that pomalidomide systemic clearance was comparable between the two groups. Covariate analysis showed pomalidomide clearance was unaffected by demographic factors, with the exception of sex, which had a difference <30%, making its clinical relevance unlikely. Furthermore, pomalidomide clearance was not significantly affected by renal function/impairment (as measured by CrCl between 20-188 mL/min).
In a previous PPK analysis, the data set included only a few patients with moderately or severely impaired renal function. Thus, there is a need for a thorough assessment of the influence of impaired renal function on pomalidomide clearance, including more data from patients with moderately or severely impaired renal function.
Following the PPK analysis, two studies were conducted to assess the specific effect of renal function on pharmacokinetics (PK), safety, and/or efficacy of pomalidomide in patients with renal impairment. CC-4047-MM-008 is an ongoing Phase 1, multicenter, open-label, dose-escalation study. 21 The primary objective of the study was to determine the PK and safety of pomalidomide when given in combination with low-dose dexamethasone in patients with rrMM and impaired renal function. CC-4047-MM-013 is an ongoing Phase 2, multicenter, open-label study to determine the efficacy and safety of pomalidomide in combination with low-dose dexamethasone in patients with rrMM and moderate or severe renal impairment, including patients undergoing hemodialysis. 22 Secondary objectives included evaluating the PK of pomalidomide in patients with various degrees of renal impairment.
The aim of this study was to use the cumulative data of patients with rrMM and degrees of renal impairment comorbidity from CC-4047MM-008 and CC-4047-MM-013 to evaluate the relationship of renal function measures (treated as both a categorical variable and a continuous variable) with pomalidomide clearance to assess the extent to which hemodialysis contributes to the elimination of pomalidomide and to optimize the start time of hemodialysis after pomalidomide administration by simulation.
Methods
Study population and PK sampling
The PPK analysis utilized data from 63 participants in two clinical studies, CC-4047-MM-008 and CC-4047-MM-013. In the PPK data set, there is an adequate distribution of patients with rrMM and various degrees of impaired renal function (Table 1) . In both studies, once-daily pomalidomide was administered orally. Institutional review boards or ethics committees (Table S1 ) approved both studies, and all study participants provided written informed consent.
Bioanalytical methodology
To determine human plasma samples for pomalidomide concentrations, a validated liquid chromatography-tandem mass 
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Pomalidomide PK in patients with relapsed or refractory multiple myeloma spectrometry (LC-MS/MS) assay was used. The lower limit of quantification was 0.25 ng/mL. As an internal standard, plasma samples were spiked with stable labeled pomalidomide. These were subsequently processed by liquid-liquid extraction and then analyzed using reversed-phase highperformance liquid chromatography (HPLC) with electrospray MS/MS detection. HPLC was used to separate peaks.
Population PK model building Selection of the most appropriate model was based on prior knowledge of pomalidomide disposition, graphical analysis, and statistical evaluation. Pomalidomide concentrationtime data, per visual inspection and data-fitting criteria, were best described by a one-compartment structure PK model. This model featured the first-order absorption rate constant (Ka), absorption lag time, apparent central compartment volume of distribution, and apparent clearance (CL/F).
The inter-individual variability (IIV) in PK parameters assumed a log-normal distribution and was modeled as follows:
with P i as the parameter value for the ith individual, P as the typical parameter value in the population, and h i as a random inter-individual parameter effect for the ith participant with a mean = 0 and variance ω 2 (ie, η~N[0, w 2 ]). IIV or residual variability was modeled as follows:
with C ij and C mij as the observed and model-predicted jth concentration in the ith participant, respectively, and e ij as the random residual effect for the jth concentration in the ith participant with a mean = 0 and variance of σ 2 . Visual predictive check (VPC) was used for model evaluation. This compared model predictions with observations and provided an evaluation of model assumption and population parameter estimates. The final PPK model's ability to describe observed concentration data was tested using simulations; VPCs were performed using 1000 data sets using the same dosages, dosing schedules, and sampling times as in the original data set.
The nonparametric bootstrap approach was used to evaluate the stability of the final PK parameter estimates and 90% CI. There were 500 bootstrap data sets, and the final model was fit to each. Every model parameter was estimated for each set; 96% of the bootstrap runs were successful. For each of the 500 estimates, median and nonparametric 90% CI (5th-95th percentiles) were calculated for each parameter.
Covariate analysis
Renal function was the key covariate for the covariate analysis. Both the Cockcroft-Gault equation 23 and the Modification of Diet in Renal Disease (MDRD) equation 24, 25 have been used to calculate CrCl and eGFR:
CrCl is capped at a physiological level of 150 mL/min. with Scr,std as serum creatinine level measured with a standardized assay.
The influence of renal function (treated as both a categorical variable and a continuous variable) on pomalidomide clearance was specifically assessed in the covariate analysis. Other typical covariates in the PPK data set included, but were not limited to, age, weight, body surface area, sex, and hepatic function markers.
The pomalidomide covariate model was developed using the stepwise covariate model-building tool of PsN. The stepwise covariate model has a fixed set of PK parametercovariate relations defined within it; predefined shapes for the pomalidomide continuous covariate model development parameter-covariate relations included either linear or power equations.
In the pomalidomide covariate model development, categorical covariates were included as follows:
with q cov representing the coefficient for the covariate effect and Z ind,k as an indicator variable representing one binary covariate form. 
Assessing effect of hemodialysis on pomalidomide PK
Hemodialysis may affect pomalidomide PK to an extent that necessitates dosage adjustment. The need for dosage adjustment arises when a significant fraction of pomalidomide is removed by hemodialysis. In such cases, a change in the dosage regimen, such as a supplemental dose following hemodialysis, may be appropriate. The hemodialysis clearance (CL D ) was estimated from the plasma concentration-time data collected on hemodialysis days from both the withdrawal ("arterial") and returning ("venous") sides of the dialyzer in patients requiring hemodialysis:
with C a as concentration in plasma entering the dialyzer (arterial line), C v as concentration in plasma exiting the dialyzer (venous line), and Q as the flow rate of blood through the dialyzer. CL D was compared with pomalidomide plasma clearance to assess the effect of hemodialysis on pomalidomide PK. Simulations were conducted to identify dosages and the starting time of hemodialysis after pomalidomide administration that achieved the goal for patients requiring hemodialysis.
Results
Analysis populations and demographics
Sixty-three participants with various degrees of impaired renal function were included in the final PPK analysis data set (Table 1) . Baseline characteristics are summarized in Table 2 
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Pomalidomide PK in patients with relapsed or refractory multiple myeloma with rrMM with normal renal function (CrCl ≥60 mL/ min), with moderate renal impairment (30< eGFR ≤45 mL/ min/1.73 m 2 ), with severe renal impairment not requiring hemodialysis (CrCl <30 mL/min or eGFR <30 mL/ min/1.73 m 2 ), and with severe renal impairment requiring hemodialysis.
Pomalidomide concentration-time profiles were adequately described by a one-compartment model with firstorder absorption. Renal function was incorporated as a categorical variable to assess the relationship of renal function measures and pomalidomide clearance. None of the other tested covariates were significant enough to be included in the final model using the stepwise covariate model based on the predefined statistical criteria for inclusion of a covariate.
The PPK parameters from the final PPK model are presented in Table 3 . The model parameters were precisely estimated with the base model as observed from the narrow 90% bootstrap CI. The estimated IIV and associated covariance were reasonably precise.
The bootstrap replicates showed similar median values of the parameters with narrow 90% CIs, compared with the original NONMEM estimates (Table 3) . These results suggest that the final model is stable and robust.
As shown in Figure 2 , VPC evaluation demonstrated that the 90% prediction intervals of the median, 5th, and 95th percentiles of simulated results could cover the observed data percentiles appropriately, and no obvious bias was noted. Overall, the observed pomalidomide 
138
Li et al concentration variability was adequately described by the estimated IIV.
Taken together, the final PPK model adequately characterized pomalidomide concentrations in the log range of −1.3666 to 5.196 (ie, 0.255-180.569 ng/mL). This enabled the use of the model to predict pomalidomide exposure for Monte Carlo simulations, making the final PPK model appropriate.
Developing dosage recommendation for patients with rrMM with different levels of renal function by Monte Carlo simulation
Per regulatory agencies' guidance, specific dosing recommendations should be constructed based on the study results using the aforementioned model for the relationships between renal function and relevant PK parameters. Simulations are encouraged as a means to identify dosages and dosing intervals for patients with different levels of renal function.
Monte Carlo simulations were conducted based on the final PPK model in which renal function was treated as a four-level categorical variable. Fifty patients with various degrees of renal impairment (normal renal function, moderately impaired renal function, severely impaired renal function not requiring hemodialysis, and severely impaired renal function requiring hemodialysis) were included in each virtual trial. Two hundred virtual trials were performed using Monte Carlo simulations.
The mean values of the plasma concentration profiles at steady state obtained from 200 Monte Carlo simulations were not remarkably different among patients with various degrees of renal impairment (Figure 3) . The mean values of the plasma exposures (area under the plasma concentrationtime curve) obtained from the simulations were not remarkably different among patients with normal renal function, moderately impaired renal function, and severely impaired renal function not requiring hemodialysis. Patients with severely impaired renal function requiring hemodialysis 
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Pomalidomide PK in patients with relapsed or refractory multiple myeloma showed 35.8% higher exposure compared with patients with normal renal function ( Table 4) .
Assessment of the relationship of renal function measures of CrCl or eGFR and pomalidomide clearance
Historically, the Cockcroft-Gault equation for calculating CrCl has been widely used to define the degree of renal impairment, and it is used commonly in the application of drug dosing guidance for patients with renal impairment. In the CC-4047-MM-008 study, CrCl was used to define the degree of renal impairment. Recently, the MDRD eGFR equation has increasingly been used as the standard in clinical practice to assess renal function. In the CC-4047-MM-013 study, eGFR was used to define the degree of renal impairment. Therefore, it is critical to assess the relationship between renal function treated as a continuous variable (CrCl or eGFR) and pomalidomide clearance. As shown in Figure Based on goodness-of-fit and statistical criteria, a onecompartment model with Ka and a reverse-hockey-stick relationship between CL/F and CrCl or eGFR adequately described pomalidomide PK (data not shown) and was chosen for the final structural PPK model ( Table 5 ).
Assessment of the extent to which hemodialysis contributes to the elimination of pomalidomide
Because pomalidomide is loosely bound to plasma proteins (12%-44%), the effect of hemodialysis on pomalidomide PK was assessed in patients with end-stage renal disease undergoing hemodialysis on both hemodialysis and nondialysis days to determine the extent to which hemodialysis contributed to the elimination of pomalidomide in both the CC-4047-MM-008 and CC 4047-MM-013 studies. CL D was calculated and the median value from seven patients was approximately 12 L/h, which is higher than pomalidomide total body clearance (5 L/h), indicating that the hemodialysis procedure removed pomalidomide from circulation. Therefore, it is critical to optimize the starting time of hemodialysis relative to pomalidomide administration. Simulations based on the final PPK model and observed CL D were conducted under two different scenarios.
• Scenario 1: hemodialysis begins after pomalidomide administration.
• Scenario 2: hemodialysis is completed before pomalidomide administration. 
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The simulated concentration vs time profiles under 4 h hemodialysis for these two scenarios are presented in Figure 5 and Figure 6 , respectively. In scenario 1, pomalidomide exposures on hemodialysis days were significantly lower than on nondialysis days under different starting times of hemodialysis. Quantitative assessment suggested that the pomalidomide exposures for scenario 1 were approximately 50%-70% of those on nondialysis days and were likely to result in insufficient pomalidomide exposures on hemodialysis days. On the other hand, in scenario 2, pomalidomide exposure was approximately 83%-91% of that on nondialysis days and provided adequate pomalidomide exposures for patients with severely impaired renal function requiring hemodialysis. When a 6 h hemodialysis procedure simulation was conducted, similar results were obtained (data not shown).
Discussion
A quantitative PPK analysis of pomalidomide PPK in both healthy individuals and patients with rrMM has been previously reported. 20 That study, which investigated the associated IIV and residual variability and assessed the effect of covariates of interest, reported that both groups showed comparable plasma exposures. However, patients with rrMM showed longer duration of terminal-phase plasma concentrations, indicating a deeper pomalidomide tissue/organ distribution. Previously, it was shown within the graphic analysis that, although renal function (determined by CrCl) appeared to have a positive correlation with CL/F, the predefined statistical significance level was not reached in the univariate covariate analysis. In patients with normal, mild, and moderate renal impairment, the geometric mean CL/F appeared . None of the other tested covariates were significant enough to be included in the final model using the stepwise covariate model based on the predefined statistical criteria for inclusion of a covariate. Monte Carlo simulation results based on the final PPK model with renal function treated as a categorical variable demonstrated comparable pomalidomide exposures among the four groups of patients, further confirming that the difference in clearance was not small (Table 4 ). 
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When renal function was treated as a continuous variable (CrCl or eGFR), the analysis demonstrated that the intercept of the total pomalidomide clearance (CL/F) vs renal function marker (3.71 and 3.96 L/h for CrCl and eGFR, respectively) curve was approximately 70% of pomalidomide total clearance (5.13 L/h), suggesting that non-renal clearance contributed roughly 70% of the total body clearance of pomalidomide, significantly more than renal clearance. In addition, the slope of the CL/F vs renal function marker (CrCl or eGFR) curve was shallow, consistent with the finding that pomalidomide was eliminated via non-renal clearance, and its total body clearance was not sensitive to changes in renal function (Table 5) . Patients from group 4 showed mildly higher exposure (39.5% and 27% for CrCl and eGFR, respectively) compared with patients from group 1 (normal renal function group).
Analyses from hemodialysis data showed that the median values of the CL D were 2-fold higher than pomalidomide total body clearance (12 and 5 L/h, respectively), indicating that the hemodialysis procedure removed pomalidomide from the blood. A simulation was conducted to optimize the start time of hemodialysis after pomalidomide administration. When the hemodialysis procedure began after pomalidomide administration, pomalidomide exposure on hemodialysis days was approximately 50%-70% of that on nondialysis days and was likely to result in insufficient pomalidomide exposures on hemodialysis days. However, when the hemodialysis procedure was completed before pomalidomide administration on hemodialysis days, pomalidomide exposure was approximately 83%-91% of that on nondialysis days and provided adequate pomalidomide exposures for patients with severely impaired renal function requiring hemodialysis.
In conclusion, this PPK analysis showed that there is no remarkable difference in pomalidomide exposures among different renal function groups, and there was a 35% higher exposure in patients with severe renal impairment requiring hemodialysis on nondialysis days. In addition, pomalidomide is cleared predominately via non-renal routes, accounting for approximately 70% of pomalidomide total body clearance. Thus, pomalidomide total body clearance is not sensitive to changes in renal function, as demonstrated by the relatively large intercept value (non-renal clearance) and shallow slope value in the relationship between pomalidomide CL/F and renal function markers (CrCl or eGFR). For patients with rrMM with end-stage renal disease requiring hemodialysis, the hemodialysis procedure removed pomalidomide from the blood; thus, pomalidomide should be administered after hemodialysis procedures.
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